Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104839 | 0.97 | HRH1 (0.35) | HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12555812 | 0.89 | HRH1 (0.31) | HRH1 | |
| Hydrochloric Acid SCHEMBL18036209 | 0.86 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL18036210 | 0.86 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL31321233 | 0.86 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL31321244 | 0.86 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12651661 | 0.83 | — | — | |
| SCHEMBL3631001 | 0.83 | — | — | |
| SCHEMBL738380 | 0.83 | — | — | |
| SCHEMBL23651491 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538072-B | Aminopyrimidine EGFR inhibitors | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| CN-112538072-A | Novel aminopyrimidine EGFR (epidermal growth factor receptor) inhibitor | 齐鲁制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| CN-106998692-B | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10577380-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2020-03-03 | — | — | US | disclosed |
| US-20190375762-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-12-12 | — | — | US | disclosed |
| US-10253040-B1 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2019-04-09 | — | — | US | disclosed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2176237-A1 | PHTHALAZINONE DERIVATIVES AS INHIBITORS OF PARP-1 | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009004356-A1 | PHTHALAZINONE DERIVATIVES AS INHIBITORS OF PARP-1 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577380-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | HRH1 3835/4885SLC6A2 4014/4885SLC6A4 4729/4885 |
| US-10253040-B1 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | HRH1 3835/4885SLC6A2 4014/4885SLC6A4 4729/4885 |
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | NR0B2, NR0B1, NR2E1 | HRH1 216/4885SLC6A2 2343/4885SLC6A4 1954/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | HRH1 1190/4885SLC6A2 4760/4885SLC6A4 4572/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | HRH1 1190/4885SLC6A2 4760/4885SLC6A4 4572/4885 |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | HRH1 3835/4885SLC6A2 4014/4885SLC6A4 4729/4885 |
| US-20190375762-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | HRH1 3835/4885SLC6A2 4014/4885SLC6A4 4729/4885 |
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | HRH1 3835/4885SLC6A2 4014/4885SLC6A4 4729/4885 |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | HRH1 3835/4885SLC6A2 4014/4885SLC6A4 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.